This section presents medications that are known to potentially lead to 'Mycobacterium avium complex infection' as a side effect. It's important to note that mild side effects are quite common with ...

The Journal of Infectious Diseases, Vol. 165, No. 6 (Jun., 1992), pp. 1082-1085 (4 pages) The product-limit incidence of Mycobacterium avium-intracellulare complex (MAC) bacteremia in 1006 human ...

In early 1979, an official of an Illinois hospital reported an increase in the number of patients from whom Mycobacterium avium complex recently had been recovered. Over the preceding 3 years ...

Patients with nontuberculous mycobacterial pulmonary disease caused by Mycobacterium avium complex had significantly improved survival if they achieved microbiological cure at the end of treatment, ...

November 11, 2009 (Philadelphia, Pennsylvania) — A subset of patients with solid organ malignancies and pulmonary Mycobacterium avium–complex (MAC) infections might fare worse if the infection is ...

The U.S. Food and Drug Administration today approved a new drug, Arikayce (amikacin liposome inhalation suspension), for the treatment of lung disease caused by a group of bacteria, Mycobacterium ...

The FDA established the Limited Population Pathway for Antibacterial and Antifungal Drugs (LPAD pathway) as part of the 21st Century Cures Act that was signed into law in December 2016. The LPAD ...

The CRISPR-based assay works by measuring MAC cell-free DNA (MAC-cfDNA) levels within patient blood samples. The test can yield results in as little as two hours, and the published preliminary ...

Mycobacterium avium subspecies paratuberculosis (MAP) is a pathogenic bacterium responsible for Johne’s disease, a chronic granulomatous enteritis primarily affecting ruminants. This disease poses ...

There are many forms of bacteria in the mycobacteria family. For example, the most common mycobacteria can lead to the onset of tuberculosis. Leprosy is caused by other mycobacteria. In addition, ...